SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Recent News & Events
FDA Fast Track designation for lead asset SAB-142 and approaching SAFEGUARD Phase 2b enrollment completion are the key near-term catalysts; recent price action is volatile with no single dominant imminent binary event within two weeks.
POSITIVEOct 13, 2026
Regulatory Designation
FDA Grants Fast Track to SAB-142 for Type 1 Diabetes
On October 13, 2026, SAB Biotherapeutics announced the FDA granted Fast Track designation to SAB-142, its disease-modifying immunotherapy for new-onset Stage 3 type 1 diabetes. Fast Track can expedite review and increase the probability of earlier approval, a positive regulatory de-risking signal for the lead program. Notably, the stock fell 5.30% on the announcement day, suggesting the market had partly anticipated the news or focused on execution risk.
Management highlighted that the 159-patient registrational SAFEGUARD Phase 2b study of SAB-142 is nearing enrollment completion, expected in Q4 2026, with topline data anticipated in 2H 2027. Completion of enrollment is a near-term operational catalyst that could reinforce confidence in the timeline, though topline data remains over a year away.
Management to Present at Chardan Healthcare Conference
SAB BIO management participated in a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20, 2026, with one-on-one investor meetings. Such events can raise visibility and generate incremental institutional interest, but are typically low-impact absent new disclosures. The stock fell 7.09% on the announcement day, indicating no positive surprise.
SABS last traded at $3.20 on October 28, 2026, up 4.23% from the prior close of $3.07. The move reflects ongoing speculative interest and elevated volatility around the clinical/regulatory narrative, but is not itself a fundamental catalyst.